Brainsway (BWAY) to Release Earnings on Wednesday

Brainsway (NASDAQ:BWAY) is expected to announce its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of $0.07 per share and revenue of $12.34 million for the quarter.

Brainsway (NASDAQ:BWAY) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. Brainsway had a return on equity of 7.35% and a net margin of 9.01%. The company had revenue of $11.54 million during the quarter, compared to analyst estimates of $11.45 million. On average, analysts expect Brainsway to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Brainsway Price Performance

Shares of BWAY stock opened at $12.10 on Tuesday. Brainsway has a 1 year low of $6.65 and a 1 year high of $13.65. The stock’s 50 day simple moving average is $11.89 and its two-hundred day simple moving average is $10.47. The company has a market cap of $228.69 million, a PE ratio of 60.50 and a beta of 1.42.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BWAY. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Brainsway in a research report on Monday, June 9th. Wall Street Zen downgraded Brainsway from a “buy” rating to a “hold” rating in a research report on Saturday.

Institutional Investors Weigh In On Brainsway

An institutional investor recently raised its position in Brainsway stock. NewEdge Advisors LLC boosted its position in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 61.5% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,828 shares of the company’s stock after purchasing an additional 7,549 shares during the quarter. NewEdge Advisors LLC owned about 0.11% of Brainsway worth $188,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 30.11% of the company’s stock.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.